Drug or Treatment Category: Radiation Therapy

NCT05477316: A Study to Assess the Efficacy of Cerebellar IMRT Combined With Cerebral SRS in Patients With Brain Metastases

NCT05477316
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Not Applicable
Drug Category: Radiation Therapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years to 99 Years (Adult, Older Adult)
Location of Metastases: Brain
Additional Notes: Patients must have a presence of multiple brain metastasis, predominantly in the posterior fossa: more than 5 metastases in the cerebellum, & less than 10 metastases in the cerebrum, visible on MRI, regardless of tumor origin
Exclusions: Patients with prior whole brain radiation (WBRT) (previous SRS is allowed for limited, up to 4 metastases, six month or more prior to the study treatment); Patients with leptomeningeal disease; Patients with severely symptomatic brain metastases
https://ClinicalTrials.gov/show/NCT05477316

NCT05438212: Comparing the Addition of Radiation Either Before or After Surgery for Patients With Brain Metastases

NCT05438212
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Not yet recruiting
Phase 3
Drug Category: Other, Radiation Therapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: Brain
Additional Notes: Patients must have 1-4 brain metastases, one of which requires resection (removal)
Exclusions: Patients with brain metastases NOT located more than 5 mm from the optic chiasm & brainstem; Patients with prior cranial radiotherapy, including whole brain radiotherapy, or SRS to the resection site (previous SRS to other lesions is allowed); Patients with evidence of leptomeningeal disease (LMD)
https://ClinicalTrials.gov/show/NCT05438212

Up ↑